 |
|
Epstein-Barr virus-associated acute disseminated encephalomyelitis successfully treated with rituximab: a case report
Seoyeon Kim, Seon-Jae Ahn, Kon Chu
encephalitis. 2021;1(3):85-88. Published online 2021 Jun 7 DOI: https://doi.org/10.47936/encephalitis.2021.00066
|
|
Citations to this article as recorded by
 Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus–Associated Meningoencephalitis
Sana Ahsan, Saba Jafarpour, Mellad M. Khoshnood, Deepti Nagesh, Eugenia Ho, Nusrat Ahsan, Jonathan D. Santoro
Journal of Child Neurology.2025; 40(1): 61. CrossRef Successful Treatment of Epstein-Barr Virus Reactivation-associated Transverse Myelitis Following Herpes Zoster with Intravenous Rituximab in a Cord Blood Transplant Recipient
Keijiro Sato, Rie Watanabe, Ichiro Ito, Ken-Ich Imadome, Masahiko Sumi, Hikaru Kobayashi
Internal Medicine.2024; 63(17): 2445. CrossRef Unpacking the CNS Manifestations of Epstein-Barr Virus: An Imaging Perspective
N. Soni, M. Ora, R. Singh, P. Mehta, A. Agarwal, G. Bathla
American Journal of Neuroradiology.2023; 44(9): 1002. CrossRef Successful treatment with rituximab for central nervous system vasculitis caused by Epstein-Barr virus-associated lymphoproliferative disorder with immunoglobulin M gammopathy
Juhee Lee, Han Sang Lee, Kon Chu
encephalitis.2022; 2(1): 14. CrossRef Epstein-Barr virus meningoencephalitis in a young immunocompetent child: A case report
Sipang Pangprasertkul, Chinnuwat Sanguansermsri, Tavitiya Sudjaritruk
Heliyon.2022; 8(10): e11150. CrossRef
|